Proximal Ventures raises debut fund to back startups bringing AI to
While established venture firms continue to attract capital, first-time fund managers are facing one of the toughest fundraising environments in years. But…
Summary
While established venture firms continue to attract capital, first-time fund managers are facing one of the toughest fundraising environments in years. But that didn’t stop Sahir Raoof, a former SignalFire investor and executive at two healthcare startups, from raising $27. Raoof’s firm, Proximal Ventures, is betting that AI can transform the tools, infrastructure, and services that support drug development. Pharmaceutical companies have historically outsourced various stages of drug development to specialized service providers, from synthesizing thousands of molecular compounds and figuring out how to manufacture drugs at scale to analyzing clinical trial data.
Positives
- While established venture firms continue to attract capital, first-time fund managers are facing one of the toughest fundraising environments in years.
Risks & concerns
- But that didn’t stop Sahir Raoof, a former SignalFire investor and executive at two healthcare startups, from raising $27.
- By using AI, these companies could deliver the same services at a lower cost and in significantly less time, he said.